+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2026-2032- Product Image
Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2026-2032- Product Image
Sale

Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337418
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Diseases In-Vitro Diagnostics Market is projected to reach USD 28.24 Billion in 2026. It is expected to continue growing at a CAGR of 6.35%, reaching USD 40.98 Billion by 2032.

Infectious diseases in-vitro diagnostics (IVD) sit at the center of global health security, enabling rapid identification of respiratory viruses, antimicrobial-resistant organisms, sexually transmitted infections, tuberculosis, HIV, hepatitis, gastrointestinal pathogens, and emerging zoonotic threats. Demand is supported by the World Health Organization’s continued focus on surveillance, the CDC’s emphasis on diagnostic stewardship, and the persistent clinical need to distinguish bacterial, viral, fungal, and parasitic infections quickly and accurately.

The market is increasingly shaped by molecular diagnostics, immunoassays, syndromic panels, point-of-care testing, digital microbiology, and laboratory automation. Procurement decisions are moving beyond test sensitivity and specificity to include turnaround time, reimbursement alignment, workflow integration, quality controls, data interoperability, and capacity to support outbreak preparedness across centralized labs, hospitals, urgent care networks, and decentralized community settings.

Transformative Shifts in the Diagnostic Landscape

The infectious diseases IVD landscape is shifting from single-pathogen, centralized testing toward connected diagnostic ecosystems that combine high-throughput laboratory platforms with rapid near-patient testing. COVID-19 accelerated acceptance of molecular testing, self-collection, decentralized sampling, and public-health reporting infrastructure, creating durable expectations for faster access and scalable testing during seasonal surges.

Healthcare systems are also prioritizing antimicrobial resistance surveillance, sepsis diagnostics, tuberculosis testing, and multiplex respiratory panels as clinicians seek earlier targeted therapy. At the same time, regulatory scrutiny, supply-chain resilience, laboratory workforce shortages, and payer pressure are influencing product design. Manufacturers that can deliver clinically actionable results, automated workflows, cybersecurity-ready connectivity, and evidence of improved patient outcomes are better positioned in this evolving IVD market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force in infectious diseases diagnostics by improving assay development, image interpretation, epidemiological modeling, workflow triage, and result interpretation. AI-enabled algorithms can support digital pathology, Gram stain review, antimicrobial susceptibility prediction, syndromic decision support, and outbreak signal detection when validated against high-quality clinical datasets and governed by transparent quality systems.

The impact is strongest when AI is embedded into laboratory information systems, electronic health records, and surveillance networks rather than treated as a standalone tool. However, adoption depends on data representativeness, regulatory validation, explainability, cybersecurity, privacy safeguards, and clinician trust. Organizations that combine AI with rigorous clinical performance evidence can improve speed, consistency, and population-level infectious disease intelligence.

Key Regional Insights: Global IVD Adoption Patterns

Asia-Pacific is a high-priority region for infectious diseases IVD due to large populations, expanding hospital infrastructure, tuberculosis and hepatitis screening programs, and rising molecular testing capacity in China, India, Japan, South Korea, Australia, and ASEAN markets. North America remains a technology and reimbursement leader, supported by strong clinical laboratory networks, FDA oversight, CDC surveillance priorities, and sustained demand for respiratory, STI, sepsis, healthcare-associated infection, and antimicrobial resistance testing.

Europe benefits from harmonized quality expectations under the EU IVDR, strong public-health laboratories, and broad antimicrobial stewardship programs, while Latin America is expanding access through public procurement, private diagnostics chains, and infectious disease screening initiatives in Brazil and Mexico. The Middle East is investing in advanced hospital diagnostics and health-system modernization, particularly across GCC countries, while Africa’s priorities center on affordable point-of-care testing, HIV, malaria, tuberculosis, hepatitis, neglected tropical diseases, and outbreak surveillance supported by national and international health programs.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding infectious diseases IVD capacity through hospital modernization, dengue and tuberculosis testing, hepatitis screening, and stronger cross-border outbreak surveillance. The GCC is prioritizing premium hospital diagnostics, national screening initiatives, digital health integration, and laboratory automation as part of broader health transformation strategies. The European Union is reshaping supplier requirements through IVDR compliance, clinical evidence expectations, traceability, and post-market performance monitoring.

BRICS countries represent substantial diagnostic demand because of large patient populations, infectious disease burden, and growing domestic diagnostic manufacturing capabilities. G7 markets drive innovation, reimbursement evidence, laboratory quality standards, and advanced molecular adoption, while NATO-aligned health systems increasingly view diagnostics as part of biosecurity, preparedness, and resilient medical supply chains. Across these groups, successful IVD strategies align clinical utility with affordability, regulatory readiness, interoperability, and dependable supply.

Key Country Insights Across Major IVD Markets

The United States leads in advanced molecular platforms, multiplex respiratory testing, commercial laboratory scale, and rapid adoption of digital reporting, while Canada emphasizes quality-assured public health testing and equitable access across provinces. Mexico and Brazil are expanding infectious disease diagnostics through public programs, private laboratory networks, and screening initiatives for respiratory infections, HIV, hepatitis, tuberculosis, and vector-borne diseases. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature hospital systems with antimicrobial stewardship priorities, sepsis management, and EU IVDR-aligned quality expectations, while Russia maintains demand for tuberculosis, respiratory, hepatitis, and hospital infection testing.

China is rapidly scaling domestic IVD innovation and hospital laboratory capacity, India is expanding affordable molecular and point-of-care testing for tuberculosis, hepatitis, HIV, and respiratory infections, and Japan prioritizes high-quality automated diagnostics for hospitals and aging-care settings. Australia and South Korea stand out for strong surveillance infrastructure, advanced hospital laboratories, antimicrobial resistance monitoring, and early adoption of digital and molecular diagnostic technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that deliver clinically actionable results within the time window needed to influence treatment, isolation, and antimicrobial stewardship decisions. Product roadmaps should emphasize multiplex flexibility, sample-to-answer automation, connectivity with laboratory information systems, electronic health record compatibility, and evidence packages that demonstrate reduced length of stay, optimized antibiotic use, improved infection control, or stronger outbreak response.

Manufacturers should diversify supply chains for reagents, plastics, enzymes, controls, and instruments while building regulatory strategies tailored to FDA, EU IVDR, and high-priority emerging-market requirements. Commercial teams should segment customers by care setting, testing volume, reimbursement pathway, laboratory workforce capacity, and public-health need. Strategic partnerships with hospitals, reference laboratories, governments, and digital health providers can accelerate adoption and strengthen long-term market resilience.

Research Methodology and Evidence Framework

This executive summary is developed using a structured secondary-research approach grounded in publicly available, authoritative sources such as WHO, CDC, ECDC, FDA, OECD, World Bank, national health agencies, peer-reviewed literature, and regulatory guidance. The methodology evaluates disease burden, testing demand, regulatory dynamics, technology adoption, healthcare infrastructure, laboratory capacity, surveillance priorities, and procurement patterns across regions, groups, and key countries.

Insights are synthesized through triangulation of public-health priorities, laboratory workflow trends, reimbursement considerations, regulatory evidence requirements, and competitive technology signals. The analysis avoids unsupported claims and focuses on verifiable indicators, including surveillance needs, antimicrobial resistance priorities, molecular testing adoption, point-of-care expansion, quality-assurance requirements, and health-system investment patterns relevant to infectious diseases IVD decision-making.

Conclusion: Diagnostics as a Core Health Security Asset

Infectious diseases IVD is evolving from episodic testing into a strategic pillar of precision care, antimicrobial stewardship, infection prevention, and public-health preparedness. The most competitive organizations will combine reliable assay performance with faster workflows, digital connectivity, scalable manufacturing, resilient supply chains, and clear clinical utility.

As health systems face respiratory virus seasonality, antimicrobial resistance, endemic infections, healthcare-associated infections, and emerging pathogens, demand will favor diagnostics that support earlier decisions and stronger surveillance. Organizations that align innovation with regulatory evidence, affordability, interoperability, and regional healthcare priorities can support sustainable growth while improving patient outcomes and population health security.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Infectious Diseases In-Vitro Diagnostics Market, by Product
7.1. Instruments
7.1.1. Automated Culture Systems
7.1.2. Immunoassay Instruments
7.1.3. PCR Instruments
7.2. Reagents & Kits
7.2.1. Immunoassay Kits
7.2.2. Microbial Culture Media
7.2.3. PCR Reagents
7.3. Software & Services
7.3.1. Consulting Services
7.3.2. Data Management Software
7.3.3. Maintenance & Support Services
8. Infectious Diseases In-Vitro Diagnostics Market, by Technology
8.1. Immunoassays
8.1.1. Chemiluminescence Immunoassay
8.1.2. Enzyme Linked Immunosorbent Assay
8.1.3. Fluorescence Immunoassay
8.1.4. Lateral Flow Assay
8.2. Microbiology Culture
8.3. Molecular Diagnostics
8.3.1. Isothermal Amplification
8.3.2. Next Generation Sequencing
8.3.3. Polymerase Chain Reaction
9. Infectious Diseases In-Vitro Diagnostics Market, by Pathogen
9.1. Bacterial
9.1.1. Enterobacteriaceae
9.1.2. Mycobacterium Tuberculosis
9.1.3. Staphylococcus Aureus
9.2. Fungal
9.3. Parasitic
9.4. Viral
9.4.1. Hepatitis Virus
9.4.2. Human Immunodeficiency Virus
9.4.3. Influenza Virus
10. Infectious Diseases In-Vitro Diagnostics Market, by Application
10.1. Diagnosis
10.2. Epidemiological Surveillance
10.3. Monitoring
10.4. Screening
11. Infectious Diseases In-Vitro Diagnostics Market, by End User
11.1. Academic Research Institution
11.2. Clinic
11.3. Hospital
11.4. Laboratory
12. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market
13. North America Infectious Diseases In-Vitro Diagnostics Market
14. Latin America Infectious Diseases In-Vitro Diagnostics Market
15. Europe Infectious Diseases In-Vitro Diagnostics Market
16. Middle East Infectious Diseases In-Vitro Diagnostics Market
17. Africa Infectious Diseases In-Vitro Diagnostics Market
18. ASEAN Infectious Diseases In-Vitro Diagnostics Market
19. GCC Infectious Diseases In-Vitro Diagnostics Market
20. European Union Infectious Diseases In-Vitro Diagnostics Market
21. BRICS Infectious Diseases In-Vitro Diagnostics Market
22. G7 Infectious Diseases In-Vitro Diagnostics Market
23. NATO Infectious Diseases In-Vitro Diagnostics Market
24. United States Infectious Diseases In-Vitro Diagnostics Market
25. Germany Infectious Diseases In-Vitro Diagnostics Market
26. China Infectious Diseases In-Vitro Diagnostics Market
27. United Kingdom Infectious Diseases In-Vitro Diagnostics Market
28. India Infectious Diseases In-Vitro Diagnostics Market
29. Japan Infectious Diseases In-Vitro Diagnostics Market
30. Russia Infectious Diseases In-Vitro Diagnostics Market
31. Brazil Infectious Diseases In-Vitro Diagnostics Market
32. Canada Infectious Diseases In-Vitro Diagnostics Market
33. Italy Infectious Diseases In-Vitro Diagnostics Market
34. Mexico Infectious Diseases In-Vitro Diagnostics Market
35. France Infectious Diseases In-Vitro Diagnostics Market
36. Spain Infectious Diseases In-Vitro Diagnostics Market
37. Australia Infectious Diseases In-Vitro Diagnostics Market
38. South Korea Infectious Diseases In-Vitro Diagnostics Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Abbott Laboratories
40.2. Becton, Dickinson and Company
40.3. Bio-Rad Laboratories, Inc.
40.4. bioMérieux SA
40.5. Danaher Corporation
40.6. DiaSorin S.p.A
40.7. Epitope Diagnostics, Inc.
40.8. F. Hoffmann La-Roche Ltd.
40.9. Grifols, S.A.
40.10. Hologic, Inc.
40.11. Illumina, Inc.
40.12. InBios International, Inc.
40.13. Koninklijke Philips N.V.
40.14. Merck KGaA
40.15. Meril Life Sciences Pvt. Ltd.
40.16. OraSure Technologies, Inc.
40.17. Qiagen N.V.
40.18. Quest Diagnostics
40.19. Quidel Corporation
40.20. Siemens Healthineers AG
40.21. Sysmex Corporation
40.22. Thermo Fisher Scientific Inc.
40.23. Trinity Biotech PLC
40.24. Vela Diagnostics
List of Figures
FIGURE 1. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED KINGDOM INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. INDIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. JAPAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. RUSSIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. ITALY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. FRANCE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SPAIN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNOASSAY INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNOASSAY INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNOASSAY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MICROBIAL CULTURE MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MICROBIAL CULTURE MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MICROBIAL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PCR REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PCR REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PCR REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CONSULTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CONSULTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CONSULTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MAINTENANCE & SUPPORT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MAINTENANCE & SUPPORT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MAINTENANCE & SUPPORT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MICROBIOLOGY CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MICROBIOLOGY CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MICROBIOLOGY CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL HEPATITIS VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL HEPATITIS VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL HEPATITIS VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL ACADEMIC RESEARCH INSTITUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL ACADEMIC RESEARCH INSTITUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL ACADEMIC RESEARCH INSTITUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL LABORATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL LABORATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL LABORATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 173. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 174. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 176. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 177. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 178. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 179. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 180. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 181. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 182. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 183. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 184. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 199. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 200. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 201. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 202. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 203. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 204. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 205. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 206. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 207. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 208. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 209. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 210. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 212. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 213. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 214. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 215. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 216. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 218. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 219. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 220. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 221. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 222. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 223. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 225. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 226. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 227. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 228. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 229. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 230. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 231. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 232. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 233. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 234. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 235. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 236. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 251. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 252. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 253. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 254. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 255. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 256. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 257. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 258. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 259. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 260. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 261. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 262. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 263. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 264. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 265. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 266. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 267. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 268. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 269. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 270. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 271. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 272. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 273. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 274. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 275. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 277. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 278. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 279. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 280. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 281. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 282. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 283. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 284. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 285. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 286. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 287. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 288. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 300. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 303. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 304. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 305. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 306. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 307. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 308. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 309. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 310. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
TABLE 311. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
TABLE 312. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 313. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 314. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 315. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 316. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 317. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 318. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 319. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
TABLE 320. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 32

Companies Mentioned

The companies featured in this Infectious Diseases In-Vitro Diagnostics market report include:
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • DiaSorin S.p.A
  • Epitope Diagnostics, Inc.
  • F. Hoffmann La-Roche Ltd.
  • Grifols, S.A.
  • Hologic, Inc.
  • Illumina, Inc.
  • InBios International, Inc.
  • Koninklijke Philips N.V.
  • Merck KGaA
  • Meril Life Sciences Pvt. Ltd.
  • OraSure Technologies, Inc.
  • Qiagen N.V.
  • Quest Diagnostics
  • Quidel Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Vela Diagnostics

Table Information

Report AttributeDetails
No. of Pages193
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 28.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 40.98 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Infectious Disease In-vitro Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Infectious Disease In-vitro Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 199 Pages
  • Global
From
Infectious Disease in Vitro Diagnostics Market Report 2026 - Product Image

Infectious Disease in Vitro Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Infectious Disease In vitro Diagnostics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Application, End User, and Geography - Product Image

Infectious Disease In vitro Diagnostics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Application, End User, and Geography

  • Report
  • 190 Pages
  • Global
From
In-Vitro Diagnostics Quality Control Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032 - Product Image

In-Vitro Diagnostics Quality Control Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
In-Vitro Diagnostics Instrument Market by Instrument Type, Technology, Configuration, Level of Automation, Application, End User - Global Forecast 2026-2032 - Product Image

In-Vitro Diagnostics Instrument Market by Instrument Type, Technology, Configuration, Level of Automation, Application, End User - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.